Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $3.71, $1.27 better than the analyst estimate of $2.44. Revenue for the quarter came in at $715.2 million versus the consensus estimate of $661.87 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.